Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 12/2009

01.12.2009 | Original Article

A genetic variant of immunoglobulin γ2 is strongly associated with immunity to mucin 1 in patients with breast cancer

verfasst von: Janardan P. Pandey, Paul J. Nietert, Kersti Klaamas, Oleg Kurtenkov

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

High levels of antibodies to mucin 1 (MUC1), a membrane-bound glycoprotein that is overexpressed in adenocarcinomas, are associated with good prognosis in patients with breast cancer. The aim of the present investigation was to determine whether GM and KM allotypes—genetic markers of IgG heavy chains and κ-type light chains, respectively—contribute to the magnitude of natural antibody responsiveness to MUC1 in patients with breast cancer. A total of 153 Caucasian subjects with breast cancer were allotyped for several GM and KM markers. These subjects were also characterized for IgG and IgM antibodies to MUC1. Anti-MUC1 IgG antibody levels in subjects who were carriers of the immunoglobulin γ2 allele GM 23 were significantly higher than in those who were noncarriers (P = 0.003). These results could potentially divide the population into high or low responders to MUC1, which has important implications for MUC1-based immunotherapeutic interventions in breast cancer.
Literatur
1.
Zurück zum Zitat Pandey JP (2001) Immunoglobulin GM and KM allotypes and vaccine immunity. Vaccine 19:613–617CrossRef Pandey JP (2001) Immunoglobulin GM and KM allotypes and vaccine immunity. Vaccine 19:613–617CrossRef
2.
Zurück zum Zitat Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Poland GA (2007) HLA supertypes and immune responses to measles–mumps–rubella viral vaccine: findings and implications for vaccine design. Vaccine 25:3090–3100PubMedCrossRef Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Poland GA (2007) HLA supertypes and immune responses to measles–mumps–rubella viral vaccine: findings and implications for vaccine design. Vaccine 25:3090–3100PubMedCrossRef
3.
Zurück zum Zitat Dhiman N, Ovsyannikova IG, Cunningham JM, Vierkant RA, Kennedy RB, Pankratz VS, Poland GA, Jacobson RM (2007) Associations between measles vaccine immunity and single-nucleotide polymorphisms in cytokine and cytokine receptor genes. J Infect Dis 195:21–29PubMedCrossRef Dhiman N, Ovsyannikova IG, Cunningham JM, Vierkant RA, Kennedy RB, Pankratz VS, Poland GA, Jacobson RM (2007) Associations between measles vaccine immunity and single-nucleotide polymorphisms in cytokine and cytokine receptor genes. J Infect Dis 195:21–29PubMedCrossRef
4.
Zurück zum Zitat Forthal DN, Gilbert PB, Landucci G, Phan T (2007) Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 178:6596–6603PubMed Forthal DN, Gilbert PB, Landucci G, Phan T (2007) Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 178:6596–6603PubMed
5.
Zurück zum Zitat Lieberman R, Stiffel C, Asofsky R, Mouton D, Biozzi G, Benacerraf B (1972) Genetic factors controlling anti-sheep erythrocyte antibody response and immunoglobulin synthesis in backcross and F2 progeny of mice genetically selected for “high” or “low” antibody synthesis. J Exp Med 136:790–798PubMedCrossRef Lieberman R, Stiffel C, Asofsky R, Mouton D, Biozzi G, Benacerraf B (1972) Genetic factors controlling anti-sheep erythrocyte antibody response and immunoglobulin synthesis in backcross and F2 progeny of mice genetically selected for “high” or “low” antibody synthesis. J Exp Med 136:790–798PubMedCrossRef
6.
Zurück zum Zitat Pandey JP, Shannon BT, Tsang KY, Fudenberg HH, Camblin JG (1982) Heterozygosity at Gm loci associated with humoral immunity to osteosarcoma. J Exp Med 155:1228–1232PubMedCrossRef Pandey JP, Shannon BT, Tsang KY, Fudenberg HH, Camblin JG (1982) Heterozygosity at Gm loci associated with humoral immunity to osteosarcoma. J Exp Med 155:1228–1232PubMedCrossRef
7.
Zurück zum Zitat Sarvas H, Rautonen N, Käyhty H, Kallio M, Mäkelä O (1990) Effect of Gm allotypes on IgG2 antibody responses and IgG2 concentrations in children and adults. Int Immunol 2:317–322PubMedCrossRef Sarvas H, Rautonen N, Käyhty H, Kallio M, Mäkelä O (1990) Effect of Gm allotypes on IgG2 antibody responses and IgG2 concentrations in children and adults. Int Immunol 2:317–322PubMedCrossRef
8.
Zurück zum Zitat Pandey JP, Page GP, Silver RM, LeRoy EC, Bona CA (2001) Anti-fibrillin-1 autoantibodies in systemic sclerosis are Gm and Km allotype restricted. Exp Clin Immunogenet 18:123–129PubMedCrossRef Pandey JP, Page GP, Silver RM, LeRoy EC, Bona CA (2001) Anti-fibrillin-1 autoantibodies in systemic sclerosis are Gm and Km allotype restricted. Exp Clin Immunogenet 18:123–129PubMedCrossRef
9.
Zurück zum Zitat Pandey JP, Nietert PJ, Mensdorff-Pouilly S, Klaamas K, Kurtenkov O (2008) Immunoglobulin allotypes influence antibody responses to mucin 1 in patients with gastric cancer. Cancer Res 68:4442–4446PubMedCrossRef Pandey JP, Nietert PJ, Mensdorff-Pouilly S, Klaamas K, Kurtenkov O (2008) Immunoglobulin allotypes influence antibody responses to mucin 1 in patients with gastric cancer. Cancer Res 68:4442–4446PubMedCrossRef
10.
Zurück zum Zitat Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ (2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82:249–293PubMedCrossRef Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ (2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82:249–293PubMedCrossRef
11.
Zurück zum Zitat von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18:574–583 von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18:574–583
12.
Zurück zum Zitat von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, van Kamp GJ, Kok A, van Uffelen K, Snijdewint FG, Paul MA, Meijer S, Hilgers J (1998) An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumour Biol 19:186–195CrossRef von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, van Kamp GJ, Kok A, van Uffelen K, Snijdewint FG, Paul MA, Meijer S, Hilgers J (1998) An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumour Biol 19:186–195CrossRef
13.
Zurück zum Zitat Schanfield MS, van Loghem E (1986) Human immunoglobulin allotypes. In: Weir DM (ed) Handbook of experimental immunology. Blackwell, Boston, pp 94.1–94.18 Schanfield MS, van Loghem E (1986) Human immunoglobulin allotypes. In: Weir DM (ed) Handbook of experimental immunology. Blackwell, Boston, pp 94.1–94.18
14.
Zurück zum Zitat Granoff DM, Suarez BK, Pandey JP, Shackelford PG (1988) Genes associated with the G2 m(23) immunoglobulin allotype regulate the IgG subclass responses to Haemophilus influenzae type b polysaccharide vaccine. J Infect Dis 157:1142–1149PubMed Granoff DM, Suarez BK, Pandey JP, Shackelford PG (1988) Genes associated with the G2 m(23) immunoglobulin allotype regulate the IgG subclass responses to Haemophilus influenzae type b polysaccharide vaccine. J Infect Dis 157:1142–1149PubMed
15.
Zurück zum Zitat Granoff DM, Holmes SJ (1992) G2 m(23) immunoglobulin allotype and immunity to Haemophilus influenzae type b. J Infect Dis 165:S66–S69PubMed Granoff DM, Holmes SJ (1992) G2 m(23) immunoglobulin allotype and immunity to Haemophilus influenzae type b. J Infect Dis 165:S66–S69PubMed
16.
Zurück zum Zitat Ambrosino DM, Schiffman G, Gotschlich EC, Schur PH, Rosenberg GA, DeLange GG, van Loghem E, Siber GR (1985) Correlation between G2 m(n) immunoglobulin allotype and human antibody response and susceptibility to polysaccharide encapsulated bacteria. J Clin Invest 75:1935–1942PubMedCrossRef Ambrosino DM, Schiffman G, Gotschlich EC, Schur PH, Rosenberg GA, DeLange GG, van Loghem E, Siber GR (1985) Correlation between G2 m(n) immunoglobulin allotype and human antibody response and susceptibility to polysaccharide encapsulated bacteria. J Clin Invest 75:1935–1942PubMedCrossRef
17.
Zurück zum Zitat Pandey JP, French MAH (1996) Gm phenotypes influence the concentrations of the four subclasses of immunoglobulin G in normal human serum. Hum Immunol 51:99–102PubMedCrossRef Pandey JP, French MAH (1996) Gm phenotypes influence the concentrations of the four subclasses of immunoglobulin G in normal human serum. Hum Immunol 51:99–102PubMedCrossRef
18.
Zurück zum Zitat Morell A, Skvaril F, Steinberg AG, Van Loghem E, Terry WD (1972) Correlations between the concentrations of the four sub-classes of IgG and Gm Allotypes in normal human sera. J Immunol 108:195–206PubMed Morell A, Skvaril F, Steinberg AG, Van Loghem E, Terry WD (1972) Correlations between the concentrations of the four sub-classes of IgG and Gm Allotypes in normal human sera. J Immunol 108:195–206PubMed
19.
Zurück zum Zitat von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdewint FG, van Kamp GJ, Schol DJ, Reis CA, Price MR, Livingston PO, Hilgers J (2000) Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 86:702–712CrossRef von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdewint FG, van Kamp GJ, Schol DJ, Reis CA, Price MR, Livingston PO, Hilgers J (2000) Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 86:702–712CrossRef
20.
Zurück zum Zitat Martin SW, Goodnow CC (2002) Burst-enhancing role of the IgG membrane tail as a molecular determinant of memory. Nat Immunol 3:182–188PubMedCrossRef Martin SW, Goodnow CC (2002) Burst-enhancing role of the IgG membrane tail as a molecular determinant of memory. Nat Immunol 3:182–188PubMedCrossRef
21.
Zurück zum Zitat Wakabayashi C, Adachi T, Wienands J, Tsubata T (2002) A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science 298:2392–2395PubMedCrossRef Wakabayashi C, Adachi T, Wienands J, Tsubata T (2002) A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science 298:2392–2395PubMedCrossRef
22.
Zurück zum Zitat Morahan G, Berek C, Miller JFAP (1983) An idiotypic determinant formed by both immunoglobulin constant and variable regions. Nature 301:720–722PubMedCrossRef Morahan G, Berek C, Miller JFAP (1983) An idiotypic determinant formed by both immunoglobulin constant and variable regions. Nature 301:720–722PubMedCrossRef
23.
Zurück zum Zitat Moxley G, Gibbs RS (1992) Polymerase chain reaction-based genotyping for allotypic markers of immunoglobulin kappa shows allelic association of Km with kappa variable segment. Genomics 13:104–108PubMedCrossRef Moxley G, Gibbs RS (1992) Polymerase chain reaction-based genotyping for allotypic markers of immunoglobulin kappa shows allelic association of Km with kappa variable segment. Genomics 13:104–108PubMedCrossRef
24.
Zurück zum Zitat Pritsch O, Hudry-Clergeon G, Buckle M, Petillot Y, Bouvet JP, Gagnon J, Dighiero G (1996) Can immunoglobulin CH1 constant region domain modulate antigen binding affinity of antibodies? J Clin Invest 98:2235–2243PubMedCrossRef Pritsch O, Hudry-Clergeon G, Buckle M, Petillot Y, Bouvet JP, Gagnon J, Dighiero G (1996) Can immunoglobulin CH1 constant region domain modulate antigen binding affinity of antibodies? J Clin Invest 98:2235–2243PubMedCrossRef
25.
Zurück zum Zitat Torres M, Fernández-Fuentes N, Fiser A, Casadevall A (2007) The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem 282:13917–13927PubMedCrossRef Torres M, Fernández-Fuentes N, Fiser A, Casadevall A (2007) The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem 282:13917–13927PubMedCrossRef
26.
Zurück zum Zitat Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34–47PubMedCrossRef Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34–47PubMedCrossRef
27.
Zurück zum Zitat Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH, von Mensdorff-Pouilly S (2007) High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett 257:47–55PubMedCrossRef Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH, von Mensdorff-Pouilly S (2007) High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett 257:47–55PubMedCrossRef
28.
Zurück zum Zitat Pandey JP, Prohászka Z, Veres A, Füst G, Hurme M (2004) Epistatic effects of genes encoding immunoglobulin GM allotypes and interleukin-6 on the production of autoantibodies to 60- and 65-kDa heat-shock proteins. Genes Immun 5:68–71PubMedCrossRef Pandey JP, Prohászka Z, Veres A, Füst G, Hurme M (2004) Epistatic effects of genes encoding immunoglobulin GM allotypes and interleukin-6 on the production of autoantibodies to 60- and 65-kDa heat-shock proteins. Genes Immun 5:68–71PubMedCrossRef
29.
Zurück zum Zitat Lenoir AA, Pandey JP, Granoff DM (1988) Antibody responses of black children to Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in relation to the Km(1) allotype. J Infect Dis 157:1242–1245PubMed Lenoir AA, Pandey JP, Granoff DM (1988) Antibody responses of black children to Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in relation to the Km(1) allotype. J Infect Dis 157:1242–1245PubMed
30.
Zurück zum Zitat Grubb R (1995) Advances in human immunoglobulin allotypes. Exp Clin Immunogenet 12:191–197PubMed Grubb R (1995) Advances in human immunoglobulin allotypes. Exp Clin Immunogenet 12:191–197PubMed
Metadaten
Titel
A genetic variant of immunoglobulin γ2 is strongly associated with immunity to mucin 1 in patients with breast cancer
verfasst von
Janardan P. Pandey
Paul J. Nietert
Kersti Klaamas
Oleg Kurtenkov
Publikationsdatum
01.12.2009
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 12/2009
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0709-4

Weitere Artikel der Ausgabe 12/2009

Cancer Immunology, Immunotherapy 12/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.